Mastocytosis is a rare group of conditions characterized by an abnormal buildup of mast cells in various parts of the body. Mast cells are a type of immune cell that plays a crucial role in allergic reactions and inflammation. Normally, mast cells help protect your body from infections, but in mastocytosis, these cells become overactive and accumulate in tissues and organs, causing a wide range of symptoms.
Symptoms of mastocytosis can vary greatly depending on the type and severity of the disease.
Common symptoms may include:
The severity of symptoms can range from mild to life-threatening, depending on individual factors and the specific type of mastocytosis.
Genetic mutations in the KIT gene are primarily responsible for causing mastocytosis. This gene normally controls the growth and function of mast cells. When mutated, particularly at a site known as codon D816, it can lead to uncontrolled growth and accumulation of mast cells. More than 80% of patients with systemic mastocytosis have the KIT D816V mutation. Other rare mutations in different regions of the KIT gene may also cause mastocytosis. In advanced cases, additional mutations in other genes, such as TET2, SRSF2, ASXL1, RUNX1, and JAK2, may also occur.
Mastocytosis is classified based on the specific organs involved and the disease’s behavior, ranging from mild and localized forms to more aggressive systemic forms that affect multiple organs.
The prognosis depends significantly on the type of mastocytosis. Individuals with cutaneous mastocytosis or indolent systemic mastocytosis typically have a normal or near-normal life expectancy. However, people diagnosed with advanced forms, such as aggressive systemic mastocytosis or mast cell leukemia, often have a poor prognosis and reduced survival time. Regardless of the type, managing symptoms and related conditions is crucial. Effective management typically involves a multidisciplinary team that tailors treatment strategies to individual needs, addresses symptoms, and monitors for potential complications.